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Cellular senescence is a stress response mechanism 
induced by different types of insults such as telomere 
attrition, DNA damage, and oncogenic mutations, 
among others [1]. First described in cultured human 
diploid fibroblasts after successive rounds of division 
[2], its main hallmarks are irreversible growth arrest, 
alterations of cell size and morphology, increased 
lysosomal activity, expression of anti-proliferative 
proteins, resistance to apoptosis, activation of damage-
sensing signaling routes. Another important 
characteristic is the regulated secretion of interleukins 
(ILs), inflammatory factors, termed the senescence-
associated secretory phenotype (SASP) [3]. 
 
As there is ample evidence placing senescent cells as 
one of the causes of age-related dysfunctions, it has 
been considered to be one of the hallmarks of aging [4]. 
 
It was recently demonstrated that elimination of 
senescent cells by genetic or pharmacological 
approaches delays the onset of aging-related diseases, 
such as cancer, neurodegenerative disorders or cardio-
vascular diseases, among others, showing that the 
chronic presence of these cells is not essential [5–7]. 
Conversely, local injections of senescent cells drive 
aging-related diseases [8, 9]. This data, together with 
that obtained from tissues of patients with different 
diseases and ages, has established causality of senescent 
cells in some aging-related pathologies [10, 11]. 
 
Current therapies targeting senescent cells are focused 
on: i) specific killing of these cells by senolytics; ii) 
specific inhibition of the secretory phenotype (anti-
SASP strategy); and iii) improving clearance of 
senescent cells by the immune system [12]. In addition, 
currently available senescence-inducing therapies for 
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Cellular senescence is a hallmark of aging, whose onset is linked to a series of both cell and non-cell autonomous 
processes, leading to several consequences for the organism. To date, several senescence routes have been 
identified, which play a fundamental role in development, tumor suppression and aging, among other processes. 
The positive and/or negative effects of senescent cells are directly related to the time that they remain in the 
organism. Short-term (acute) senescent cells are associated with positive effects; once they have executed their 
actions, immune cells are recruited to remove them. In contrast, long-term (chronic) senescent cells are 
associated with disease; they secrete pro-inflammatory and pro-tumorigenic factors in a state known as 
senescence-associated secretory phenotype (SASP). In recent years, cellular senescence has become the center of 
attention for the treatment of aging-related diseases. Current therapies are focused on elimination of senescent 
cell functions in three main ways: i) use of senolytics; ii) inhibition of SASP; and iii) improvement of immune 
system functions against senescent cells (immunosurveillance). In addition, some anti-cancer therapies are based 
on the induction of senescence in tumor cells. However, these senescent-like cancer cells must be subsequently 
cleared to avoid a chronic pro-tumorigenic state. Here is a summary of different scenarios, depending on the 
therapy used, with a discussion of the pros and cons of each scenario. 
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cancer stop tumor growth while causing accumulation 
of senescent cells [13, 14], which subsequently become 
a problem for the organism [15]. 
 
This review will summarize the hypothetical scenarios 
that each anti-cell senescence approach (described 
above) could face, either alone or in combination, with 
a discussion of open questions that should be kept in 
mind when targeting senescent cells.  
 
Triggers of cell senescence 
 
The onset of senescence in healthy tissue occurs in 
response to different internal and external stimuli, such 
as telomere attrition, DNA damage (alkylating agents, 
radiation), oncogene activation, mitochondrial 
dysfunction, and spindle, epigenetic, endoplasmic 
reticulum (ER) and proteotoxic stress [16–19]. The  
type and duration of the stimulus dictates the final  
effect on the senescent cells [20]. These cells display  
a characteristic phenotype comprising specific 
cell/nuclear morphology (increased size, abnormal 
shape and nuclear envelope changes), apoptosis 
resistance, chromatin redistribution (senescence-
associated heterochromatin foci and senescence-
associated distension of satellites), epigenetic markers 
(e.g. H3K9Me3), lipofuscin accumulation, SASP, and 
overexpression of proteins such as p53, p16Ink4a, 
p21WAF1, Differentiated Embryo Chondrocyte-expressed 
gene 1 (DEC1) and senescence-associated β-Gal (SA-β-
Gal) [13, 21–24]. To date there is no universal marker 
for senescence, and identification of senescent cells is 
based on the combined detection of two or more 
phenotypic aspects mentioned above, such as SA-β-Gal, 
p16Ink4a or p21WAF1 [10]. 
 
One of the characteristic phenotypic hallmarks of cell 
senescence is the secretion of a plethora of factors that 
affect their environment (SASP), which also serves as 
a call for the immune system to recognize and 
eliminate the senescent cells [3, 25]. Among the SASP 
factors that seem responsible for attraction of immune 
cells are CSF (colony stimulating factor 1), CXCL-1 
(chemokine C-X-C motif ligand 1), MCP-1 (monocyte 
chemoattractant protein 1) and ICAM-1 (intercellular 
adhesion molecule 1) [25]. In this scenario of acute or 
short-term senescence, the tissue returns to normal 
after a regeneration process [17] (Figure 1, steps 1-4). 
The regeneration is a fundamental process to avoid 
tissue atrophy and dysfunction. In this scenario of 
replacement of senescent cells, we should keep in 
mind the different capacity of renewal of some  
tissues with respect to others, and the exhausted or 
damaged state of stem cells that can lead to 
functionally compromised differentiated cells or 
carcinogenesis [26]. 
Implication of cell senescence in disease 
 
Acute senescent cells play a direct role in tumor 
suppression, efficient wound healing, embryogenesis, 
placental formation, and tissue regeneration, among other 
processes [17]. At this point, both their onset and primary 
effect are positive for the organism [17, 20]. 
 
When senescence-inducing stimuli persist and decrease 
the ability of the immune system to recognize and 
eliminate senescent cells (by either immunosenescence 
or immunosuppression), these cells accumulate. The 
continual presence of senescent cells negatively affects 
their environment, inducing damage, instability or 
senescence in other cells through SASP [1, 27]. Over 
time, these “secondary” damaged cells can become 
either pro-tumorigenic or senescent, which increases the 
cellular instability of the tissue, leading to dysfunction 
and disease [27] (Figure 1, steps 5 and 6). In this sense, 
some SASP factors play a direct role in fibroblast 
activation and uncontrolled fibrotic scarring [28]. 
 
Chronic senescent cells (also termed “zombie” cells) 
have been associated with the onset of several diseases 
[1, 10, 13, 17]. In the last few years there have been 
extensive studies to elucidate the causative role of 
senescence in the onset of different pathologies [17]. 
These studies were mainly based on: i) detection of 
senescent cells in tissues/organs from patients or animal 
models; or ii) improvement in tissue/organ functions 
upon removal of senescent cells in mice, by either 
genetic or pharmacological interventions. This is a list 
of some age-related diseases where cellular senescence 
seems to play an important role: 
 
Cancer 
Aging is the main cause of cancer [29], and the 
presence of senescent cells in aged tissues or xenograft 
models correlates with the incidence of cancer [30, 
31]. Their specific removal led to a delay in tumor 
formation and reduced metastasis [6]. It is also 
important to note that both senolytics and senomorphics 
are currently being used in clinical trials for the 
treatment of numerous types of cancer, such as leukeia, 




Senescent cell accumulation has been detected at sites of 
brain pathology [7, 32, 33]. The presence of senescent 
astrocytes correlates with the onset of pathologies such as 
Parkinson’s and Alzheimer’s disease [34]. Interestingly, 
Tau protein induces cellular senescence in neurons, and 
specific clearance of senescent astrocytes and microglia, 
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reduced Tau-containing neurofibrillary tangle, neuron loss 
and ventricular enlargement [7, 8]. Moreover, it has been 




Senescent cells play a key role in atherosclerosis, and 
their specific removal reduced progression of the 
disease [35]. Moreover, senescent macrophages seem to 
contribute to coronary heart disease, and cell senescence 
in the aorta increases vascular stiffness [13]. 
 
Osteoarthritis 
This degenerative disease causes the joints to become 
painful and stiff, and accumulation of senescent cells 
correlates with its progression [36]. In mouse models, 
local injections of these cells induce an osteoarthritis-
like condition [9], whereas their clearance improves 
health by attenuating development of post-traumatic 
osteoarthritis [37].  
 
Type 2 diabetes 
Aging is the main cause of type 2 diabetes, and there is 
association between disease progression and detection 
of senescent markers. Senescent β-cells affect glucose 
homeostasis, although further work is needed to 
elucidate the exact role of senescence [20, 38, 39]. 
 
Kidney-related diseases 
Diseases such as glomerulosclerosis and nephropathies 
are associated with an increase of senescent cells [10]. 
Remarkably, when these cells were removed by genetic 
approaches, kidney functions improved [6]. 
 
Idiopathic pulmonary fibrosis (IPF) 
This chronic lung disease results in scarring, affecting 
primarily older adults. Tissues from IPF patients 
display some phenotypical characteristics of senescent 
cells, and when these cells were removed by 
senolytics, pulmonary functions improved [104]. 
 
Cachexia 
In this disease adipocyte differentiation is disrupted by 
senescent cells, causing weight loss, muscle wasting 
and loss of body fat, leading to metabolic dysfunction 
and loss of adaptive thermogenic capacity [10]. When 
senescent cells were removed, tissue homeostasis 




Figure 1. The onset of cellular senescence in normal tissue takes place in response to different stimuli (1). Some SASP factors are involved in 
immune cell recruitment, which act in the clearance of the senescent cells (2). Then, to restore the normal tissue, a regeneration process is 
necessary (3, 4). When a combination of persistent damage and immune system decay occurs, senescent cells accumulate, creating a pro-
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inflammatory and pro-tumorigenic environment and fibrotic tissue. Over time, this leads to disease, such as cancer progression, insulin 
resistance, osteoarthritis, atherosclerosis, and brain pathologies, among others (5, 6). 
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Cataracts 
Characterized by opacity of the lens of the eye [109], 
the lens capsules from patients suffering cataracts show 
accumulation of senescent human lens epithelial cells 
[105]. Removal of these cells by genetic approaches 
decreased the incidence of cataracts in old mice [6]. 
 
Liver diseases 
The presence of senescent cells correlates with the onset 
of liver fibrosis, cirrhosis and non-alcoholic fatty liver 
disease. Elimination of these cells reduced liver fat 
accumulation [10, 106]. 
 
Metabolic syndrome 
A collection of metabolic disorders such as increased 
blood pressure, high blood sugar, excess body fat 
(around the waist) and abnormal cholesterol levels. 
Endothelial cell senescence is involved in systemic 
metabolic dysfunction and glucose intolerance [13, 
107].  
 
Erectile dysfunction  
The presence of senescent cells is directly related to 
endothelial dysfunction. SASP factors seem mediate 
this effect, and importantly, removal of senescent cells 
led to improvement of erectile function in mice [40]. 
Altogether, this data highlights the importance of 
targeting these cells in order to delay or cure different 
diseases. 
 





An option to eliminate the negative effects of chronic 
senescent cells is to kill them specifically, using 
compounds called senolytics (Figure 2), which target 
pathways activated in senescent cells [16]. The list of 
these senolytic tool compounds is extensive and 
continuously growing. In Table 1 are shown the 
noteworthy ones. Chronic/periodic administration of 
senolytics kills senescent cells that are generated in the 
tissues, and the immune system is responsible for 
clearing apoptotic bodies for subsequent regeneration 
with new cells (Figure 2, steps 1-3).  Senolytics target 
key proteins mainly involved in apoptosis, such as Bcl-
2, Bcl-XL, p53, p21, PI3K, AKT, FOXO4 and p53. See 
Table 1 for references. 
 
Although senolytics are supposed to be specific for 




Figure 2. Treatment with senolytics to specifically kill senescent cells (1). Over time, these apoptotic bodies will be cleared by the immune 
system (2). Finally, a regenerative process will lead to normal tissue functions (3). Normal cells could be affected by either the lack of 
specificity of the senolytics or chronic treatment, leading to tissue dysfunction (4). 
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Table 1. List of senolytics and their targets. 
Senolytic Target/function References 
 Apoptosis  
Dasatinib (D) Inhibitor EFNB*-dependent suppression of apoptosis [51] 
Quercetin (Q) PI3K/AKT, BCL-2, p53, p21, Serpine [51] 
ABT 737 BCL-W and BCL-XL inhibitor [52] 
ABT 263 (Navitoclax; UBX0101) BCL-2, BCL-XL and BCL-W inhibitors [37, 53, 54] 
A1331852, A1155463 BCL-XL [55] 
Fisetin PI3K/AKT and ROS [55] 
FOXO4-related peptide (DRI) Inhibitor of FOXO4-p53 interaction [44] 
Delivery options**   
Gal-encapsulated cytotoxics SA-β-Gal [42] 
*AKT; protein kinase B. BCL; B-cell lymphoma. EFNB; ephrin ligand B. FOXO; forkhead box proteins O. PI3K; 
phosphatidylinositol 3-kinase. ROS; reactive oxygen species. 
**It helps improve senolysis by directed targeting. 
 
effects since the administration is not directed [41] 
(Figure 2, step 4). In this regard, a new strategy has 
been recently described to specifically target senescent 
cells in mice, using nanocapsules containing toxins (or 
senolytics) [42]. The outer layer of these nanocapsules 
are composed of substrates for enzymes that are 
overexpressed in senescent cells. In this way, the toxin 
(senolytic) will only be released inside senescent cells, 
killing them [42]. Thus, these nanocapsules are a 
vehicle to specifically deliver any type of senolytic into 
senescent cells in mice. The specificity of the delivery is 
important in non-targeted senolytics (natural product 
derivatives with less defined biological activities), such 
as quercetin and fisetin. 
 
Though there have been numerous reports showing the 
benefits of senolytics, it is important to highlight the 
recently described effects of dasatinib + quercetin (D + Q) 
treatment on lifespan in old animals [43]. Transplant of 
senescent cells into healthy mice caused physical 
dysfunction, which was reversed by oral administration of 
D + Q [43]. Also, clearance of senescent neurons 
improved neurological functions in transgenic mice 
mimicking Tau aggregation-dependent neurodegenerative 
disease [8]. It is also important to note that the treatment 
with the peptide FOXO4-DRI restored renal functions in 
both old (normal) mice and mice with accelerated aging 
[44]. As indicated above, some senolytics are currently 
being used in clinical trials for treating different diseases 
[16]. In this sense it is important to mention that MDM2 
inhibitors, targeting p53, are also in clinical phases as  
anti-cancer therapies [45]. 
 
Remaining questions 
There is reasonable doubt about the fate of the dead 
senescent cells, especially when the immune system of 
the patient is depressed (by either immunosenescence or 
immunosuppression). The accumulation of these 
apoptotic bodies may have undesired side effects (i.e. 
further release pro-inflammatory factors in an already-
damaged tissue) [10]. Also, as indicated before, the 
possible side effects of periodic/chronic treatments 
should not be ignored. In fact, toxic effects after systemic 
administration of BCL family inhibitors have been 
described in patients, such as thrombocytopenia and 
neutropenia [41]. It would be desirable that treatments 
with senolytics are as sporadic as possible, without 
affecting efficacy. Lastly, and as indicated above, the 
regeneration process is an important issue to be analyzed 
in the tissues where senescence clearance has taken 
place. 
 
SASP inhibitors (or senomorphics) 
 
Another strategy to inhibit the functions of senescent cells 
is through the specific silencing of SASP [16, 46], the 
complex mixture of soluble factors such as cytokines, 
chemokines, growth factors, proteases and angiogenic 
factors that mediates the paracrine and autocrine functions 
of senescent cells [3, 25] (Figure 3). The qualitative and 
quantitative composition of this secretome is different 
depending on the cell type and the senescence-inducing 
stimulus, and becomes fully active a few days after the 
persistent stimulus [3, 47, 48]. Senomorphics inhibit 
SASP functions by targeting pathways such as p38 
mitogen-activated protein kinase (MAPK), NF-κB, IL-1α, 
mTOR and PI3K/AKT (Table 2), which act at the level of 
transcription, translation or mRNA stabilization [21]. 
Alternatively, inhibition may be achieved by specific 
neutralizing antibodies against individual SASP factors 
(protein function inhibition), as is the case for IL-1α, IL-8 
and IL-6.  
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As IL-1α plays a direct role in SASP regulation, 
targeting either the receptor (IL-1αR) or the ligand (IL-
1α) leads to decreased global SASP expression, with 
special emphasis on oncogene-induced senescence 
(OIS) [49, 50]. 
 
Importantly, the MABp1 antibody (neutralizing anti-
human IL-1α monoclonal) has proven efficient in 
clinical trials against type 2 diabetes, sarcopenia and 
inflammation [56–58], diseases in which senescent cells 
play an important causative role [10].  
 
IL-8 is a member of the CXC motif chemokine 
upregulated in SASP, and is associated with some types 
of cancer [50]. ABX-IL-8 is a humanized monoclonal 
antibody against IL-8 that acts as an antagonist, 
impairing IL-8 signaling. Treatment with ABX-IL-8 
attenuates the growth of some cancer xenografts  
models [59]. 
 
IL-6 is a pleiotropic cytokine also upregulated in SASP 
that is involved in tumor proliferation, invasion and 
immunosuppression. Specific inhibition of IL-6 by a 
neutralizing monoclonal antibody (Mab-IL-6.8) 
completely abolished JAK/STAT signaling [50, 77] and 
relieved symptoms of arthritis in a primate model 
(Olokizumab) [78]. Arthritis has also been causally 
associated with the presence of senescent cells [37]. 
Finally, SASP-silenced/attenuated senescent cells should 
be recognized by the immune system for subsequent 
clearance and regeneration (Figure 3, steps 2 and 3). 
 
Remaining questions 
One doubt about this strategy is how SASP-
silenced/attenuated senescent cells would be cleared. 
Given that some SASP factors are involved in the 
recruitment of immune cells, SASP inhibition could 
make senescent cells effectively “invisible” to the 
immune system, therefore remaining chronically within 
the tissue. In fact, two senomorphics (apigenin and 
kaempferol) showed inhibition in cultured cells of SASP 
components involved in immune cell recruitment, such as 
CXCL-1 and CSF [65]. What would the influence of 
SASP-silenced senescent cells be in the tissue? Perhaps 
instead of being dysfunctional, the tissue would be non-
functional. 
 
Likewise, as senomorphics require chronic/continuous 
treatment, a major problem of these types of SASP 
inhibitors is the lack of specificity for senescent cells. 
Perhaps inhibition of individual SASP components by 
neutralizing antibodies (as described above) would 
minimize the potential side effects. As indicated for 
senolytics, it would be desirable if over time, the 
treatments with senomorphics were as sporadic as 




Figure 3. Treatment with senomorphics to inhibit SASP factors in senescent cells (1). Over time, these cells will be removed by immune cells 
(2). Finally, a regenerative process will lead to normal tissue functions (3). In aged or immunosuppressed individuals, this strategy would lead 
to an accumulation of SASP-silenced/attenuated senescent cells (4). 
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Table 2. List of senomorphics and their targets. 
SASP inhibitor Target/function* References 
SB 203580 p38 MAPK** inhibitor ([60] Reviewed by [12]) 
UR-135756, BIRB 796 p38 MAPK inhibitor [61] 
Resveratrol NF-ƙB inhibitor (IĸB-kinase inhibitor), AMPK and SIRT1 activator, others [62–64] 
Apigenin, Wogonin, Kaempferol NF-ƙB inhibitors (IĸB-zeta) [65] 
Metformin 
Inhibition of IKK/NF-ƙB, mitochondrial electron 
tranport, mitochondrial GPDH, and KDM6A/UTX, 
AMPK activator, others 
[66–70] 
Cortisol/corticosterone IL-1α/NF-ƙB pathway inhibitors [71] 
NDGA ROS (free radical scavenger) [72] 
Rapamycin mTOR inhibitor, membrane-bound IL-1A translation inhibition, prelamin A, 53BP1 [73]  [74] [110] 
Ruxolitinib Inhibition of JAK1/2 and ROCK [75, 76] 
*For many of the SASP inhibitors listed there have been described several targets. 
**53BP1; p53 binding protein 1. AMPK; AMP-activated protein kinase. IKK; IĸB kinase. JAK; Janus kinase. KDM6A/UTX; lysine 
demethylase 6A. MAPK; mitogen-activated protein kinase. mTOR; mammalian target of rapamycin. NDGA; 
nordihydroguaiaretic acid. NF-ƙB; nuclear factor kappa light chain enhancer of activated B cells. ROS; reactive oxygen species.  
 
Improving immune system function 
 
A third strategy to target senescent cells is to strengthen 
the immune system for efficient recognition and 
elimination of these cells, a process termed immuno-
surveillance (Figure 4, steps 1-3). The role of the 
immune system in the elimination of senescent cells is 
fundamental, and a decline in immune function is 
associated with an increase in the number of senescent 
cells and finally, disease (Figure 4, step 4) [12, 20, 79, 
80]. 
 
In this regard, there are two strategies: i) improving the 
specific anti-senescent cell functions; and ii) general 
enhancement of immune functions (to avoid senescence 
of immune cells involved in recognition of senescent 
cells). 
 
Anti-senescent cell functions have been described in NK 
cells, macrophages and CD4+ T cells [20, 81]. Since these 
functions take place through membrane receptors, one 
option is to increase the binding affinity of the involved 
receptors. In this sense, the use of chimeric antigen 
receptor (CAR) T cells to target specific senescent-related 
molecules would be an attractive approach. This strategy 
is currently showing extraordinary results as anti-cancer 
therapy [82]. Alternatively, specifically increasing the 
surface expression of these receptors in senescent cells 
could be attempted. NK cells recognize the CD58/ICAM1 
receptor present in senescent cells [83]. In the case of 
macrophages this recognition is not clear, and may occur 
through modified membrane receptors in senescent cells 
(glycans, lipids or vimentin), recognized by receptors 
present in macrophages such as CD36, IgM, SIRPα, and 
leptins. For T cells this process would be mainly mediated 
by TCRs [84]. 
 
Another possibility is to reduce the number of senescent 
immune cells, perhaps by depletion using specific 
antibodies recognizing surface markers of senescence, 
and in this way “rejuvenate” the immune system [84]. 
In this sense the recent identification of a targetable 
senescent cell surface marker supports this strategy 
[85]. 
 
NK and T cell functions decrease in older individuals. 
The constitutive activation of the nutrient-sensing 
component adenosine 5´-monophosphate-activated 
protein kinase (AMPK) seems to play a central role in 
this process [86]. Thus, an alternative approach to 
increase functions of these immune cells is to target 
AMPK functions, as the p38 MAPK inhibitor does [87]. 
Another approach would be to inhibit the killer cell 
lectin-like receptor G1 (KLRG1, or CD57 in humans), 
which increases on NK and T cells of older individuals. 
Activation of KLRG1 in NK cells is associated with 
activation of AMPK (via protein stabilization), which in 
turn would inhibit cell functions. In the case of CD8+ T 
cells, this mechanism may involve other inhibitory 
receptors, such as programmed death 1 (PD-1) and 
cytotoxic T lymphocyte antigen 4 (CTLA-4) [86].  
 
The down-regulation of the CD28 receptor is a hallmark 
of human CD8+ T cell senescence. Interestingly these 
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senescent T cells have been found not only in old 
individuals (aging process), but also associated to 
diseases such as cancer and arthrosis [83], which are 
aging-related diseases where senescent cells seem to 
play a causative role, as discussed above.  
 
This fact reinforces the idea of a pivotal role of immune 
cells by delaying the onset of diseases related to the 
accumulation of chronic senescent cells. In this regard, a 
recent article shows that mice lacking the main cytotoxic 
functions of NK and T cells (perforin pathway), 
accelerates both senescent cell burden and aging [80]. 
 
Some current anti-cancer therapies are based on 
immunotherapy, that stimulates the immune system to 
recognize and kill disease-associated cells based on 
differences in the expression of antigens between 
pathogenic and normal cells [88]. Immunotherapy is 
currently used not only for different types of cancer, but 
also for infectious diseases, Alzheimer’s disease, and 
even some types of addictions [89, 90]. Senescent cells 
display a characteristic phenotype, which make them 
suitable targets for this strategy. Cell and antibody 
mediated responses are possible approaches, however, 
the specificity of senescent antigens would be the 
bottleneck to avoid undesirable side effects [108]. 
Remaining questions 
Improving immune system functions to target senescent 
cells could be difficult in scenarios such as immuno-
senescence (in older individuals or patients suffering 
from premature aging of the immune system [91]) or 
immunosuppression (i.e. patients treated with 
corticosteroids or radiation, in cases of organ transplant, 
autoimmune disease or cancer). CAR-based strategies 
and immune system “rejuvenation” would be 
personalized treatments, and thus very time consuming 
and expensive. These strategies would rely on specific 
(universal) senescence receptors, and a limiting factor 
when detecting cell senescence is the lack of universal 
markers [13]. Although novel technologies are making 
detection of senescent cells in tissues more reliable [92, 
93], the use of a combination of different biomarkers is 
still necessary for confirmation. Thus, personalized 
treatment targeting at least 2 senescence markers would 
increase the challenge and difficulty of the process. 
 
Moreover, the described connection between NK and T 
cell activation and nutrient-sensing machinery suggests 
that dietary interventions could be a promising approach 
to maintain a healthy immune system in older 
individuals, and thus the ability to efficiently clear 




Figure 4. Improving immune system functions to efficiently remove senescent cells (1). A robust immune system targets senescent cells, 
leading to their removal (2). Then a regenerative process will maintain normal tissue functions (3). In situations where the immune system 
decays (e.g. immunosenescence or immunodepression), there will be an accumulation of senescent cells, increasing instability in the 
tissue/organ (4). 
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expression of either the receptor itself or other receptor 
related to T cell activation) could be another attractive 
approach to delay the senescence process in CD8+ T 
cells. Last, but not least, it is important to keep in mind 
that a general stimulation of the components of the 
immune system might also induce autoimmune diseases 
or may also promote some hematopoietic malignancies 
[94, 95]. 
 
Targeting senescent cancer cells 
 
A way to stop cancer progression is to induce 
senescence in tumor cells (TIS; therapy-induced 
senescence), through treatments targeting key pathways 
activated in highly proliferative cells. These treatments 
include DNA damage inducers (e.g. mitoxantrone, 
doxorubicin, γ-radiation), and inhibitors of Aurora 
kinase A (i.e. MLN8054, alisertib) and CDK4/6 
(abemaciclib, palbociclib, ribociclib), among others [14, 
96–98]. While stopping tumor growth, TIS becomes a 
problem for the organism in the long-term, as cancer 
survivors have a higher incidence of age-related 
diseases linked to senescence, including cardiovascular 
disease, neurodegeneration, sarcopenia and secondary 
neoplasia [19]. Cancer cells that escape from TIS (or 
“senescence-like” cancer cells) display some features, 
such as polyploidy, stemness and aggressiveness. It has 
been calculated that only 1 in 106 of senescent cancer 
cells escape from TIS. Although it seems to be a rare 
event, it occurs [99, 100]. 
 
At this point, it is conceivable to imagine a tissue that is 
already damaged, not only by tumor cells but also a mix 
of pre-tumorigenic and senescent cells, together with 
fibrosis and SASP (Figure 5). The newly senescent cells 
(from the tumor; TIS) would increase the level of SASP 
in the tissue, leading to: i) growth of new tumors (or 
sprouts of the former); ii) senescence induction in 
neighboring cells; as well as iii) an increase in fibrotic 
tissue. This scenario would lead to an exacerbation of 
the pathology that was described in the starting point 
(step 3). 
 
One solution to this situation would be to combine TIS 
(effective therapy to stop the growth of the tumor that is 
already present) with one or more of the three anti-
senescent strategies presented above (senolytics, 
senomorphics and improved immune function) (Figure 
5). Then clearance and tissue renewal processes will be 




Figure 5. Inducing senescence in tumor cells will lead to an accumulation of senescence burden (1). The pro-inflammatory and pro-
tumorigenic environment (more SASP factors) leads to exacerbation of the pathology (e.g. cancer relapse, fibrosis, inflammation) (2, 3). By 
targeting senescent cells with a combination of the approaches currently used, a better final scenario is possible (4).  Fibrotic scarring may be 
treated by other means, or cured over time. 
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Table 3. Comparison of the therapies presented in this review. 
Therapy Pros Cons 
Senolytics High specificity 
- Targeted drugs 
Sporadic treatments 
- Depending on compound efficacy 
 
Low specificity 
- Non-targeted compounds 
Side effects 
- BCL family inhibitors 
Increase in apoptotic bodies 
Chronic treatments 
- Depending on compound efficacy 
Senomorphics High specificity 
- Targeting individual SASP 
components 
Sporadic treatments 
- Depending on compound efficacy 
Low specificity 
- Targeting central pathways 
Chronic treatments 
- Depending on compound efficacy 









Time consuming and expensive 
- Personalized treatments 
Low specificity 
- General activation 
Side effects 
- Autoimmunity? 
- Hematopoietic malignancies? 
Chronic treatments 
Patients affected by immunosuppression and/or 
immunosenescence 
TIS High specificity 
- Specific targets 
Sporadic treatments 
Stops tumor growth 
Possibility to combine with other therapies 
Low specificity 
- General damage (chemo-radiotherapies) 
Side effects 
- New tumors 
- Fibrosis 
Chronic treatments 
Increasing senescence burden 
 
Remaining questions 
Importantly these therapies would rely on the state of the 
patient´s immune system, and many patients have been 
affected by treatments they have received previously 
(immunosuppression), or by age (immunosenescence). In 
this sense, it is likely that in some cases it would only be 
necessary to inhibit SASP and not specifically induce 
death of the senescent cells, to avoid depending on the 
immune system for removal of apoptotic bodies. 
 
And what about fibrosis? Fibrotic scarring can resolve 
over time, being replaced by new tissue. However, if 
this process is not completed (e.g. older people), the 
normal function of key organs can be compromised. 
Thus, alternative therapies should be kept in mind to 




Targeting senescent cells has become an alternative 
therapy for treating different aging-related diseases. 
This therapy can be approached on three levels: i) 
specific killing of these cells; ii) inhibition of their 
secretory phenotype, therefore making them less 
efficient; and iii) improving our immune system for 
elimination of senescent cells. 
 
The use of senolytics and senomorphics are showing 
promising results, although is still too early to draw 
conclusions. It is necessary to improve the specificity of 
these compounds, as well as optimize the treatment (i.e. 
dosage) to avoid unwanted effects. In this sense, progress 
has been made on the specific delivery of drugs into 
senescent cells by using nanocapsules. This elegant 
approach may overcome the problem of specificity of 
senolytic tool compounds when administrated in a chronic 
manner [42]. Importantly, senolytics and senomorphics 
are found in natural compounds, showing new 
(nutraceutical) approaches to treat aging-related diseases, 
although in a non-targeted way [102]. 
 
The “transformation” of normal cells into senescent 
ones is accomplished by a multitude of internal and 
external stressors in different physiological situations. 
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Cancer cells can become senescent as well after 
different therapies, though the new tumor-induced 
senescent cells (TIS) generated are harmful in the long 
term. In this scenario, the three options presented here 
to either eliminate or “silence” the senescent cells are 
important to combat TIS. The combination of these pro- 
and anti-senescence approaches (TIS + senolytics 
and/or senomorphics and/or improved immune system), 
will play an important role in the cure of some types of 
cancer [98].  
 
In future clinical trials focused on eliminating senescent 
cells, it will be important to determine when to initiate 
the treatments (age of the patients), the schedule 
(continuous, periodic and/or sporadic), as well as the 
specific markers to determine the efficacy of the therapy 
(see Table 3 for comparison of the therapies presented 
in this review). Clinical trials should be supported by 
robust preclinical results obtained in proper animal 
models. 
 
Senescent cells are the cause of several age-related 
diseases, which account for a high percentage of all 
causes of death worldwide and an expansion of 
morbidity. Likewise, it is estimated that by the year 
2045, the number of people older than 60 will surpass, 
for the first time in history, the number of people under 
the age of 15 [103]. Thus, the approaches presented in 
this review highlight the urgent need for new therapies 
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